InvestSMART

argenx SE (NASDAQ: ARGX) - Share Price

Current share price for ARGX : $1,023.210 35.69 (3.37%)+

Currency: USD ($)

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It , was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

ARGX General Information +

NASDAQ Code ARGX
Industry/Sector Biotechnology
Market Cap ($M) 64,013
ARGX Share Price $1,023.210
Day High $1,053.000
Day Low $1,018.600
Last Close $1,058.900
ARGX Share Price Movement $35.69 ( 3.37% )
Prices as at 4:04, 29 Aug 2026
+Security prices are at best end-of-day and are indicative only.

ARGX Financial Summary

Operating Revenue Per Share Price to Operating revenue Price to free cash flow Earnings Yield PE Ratio Dividend Yield Forward Dividend Yield Forward Earnings Yield
$15.88 $65.01 $74.74 2.57% 38.98 n/a n/a 2.75

ARGX Calendar of Events

Created Date Changed Date Event
04 August 2026 04 August 2026 Company Meeting

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.